At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5,278 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rivaroxaban Evaluation in Real Life Settings
In Brief
An observational study for Atrial Fibrillation and Stroke. Completed, enrolled 5,278 participants across 2 sites in 2 countries.
Detailed Summary
To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Stroke
CountriesFrance, United Kingdom
CollaboratorsBayer
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionMay 2019
Study CompletionSep 2020
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartJul 1, 2015
Primary CompletionMay 30, 2019
Study CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.1 years ago